(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 39.55% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.12%.
Harrow's revenue in 2026 is $268,675,000.On average, 10 Wall Street analysts forecast HROW's revenue for 2026 to be $13,359,771,100, with the lowest HROW revenue forecast at $12,804,372,006, and the highest HROW revenue forecast at $13,773,152,037. On average, 8 Wall Street analysts forecast HROW's revenue for 2027 to be $20,142,349,570, with the lowest HROW revenue forecast at $17,497,680,728, and the highest HROW revenue forecast at $22,563,740,520.
In 2028, HROW is forecast to generate $27,339,054,478 in revenue, with the lowest revenue forecast at $23,789,346,038 and the highest revenue forecast at $30,798,184,408.